Bay Area Lyme Foundation Now Accepting Applications for $450,000 in Emerging Leader Award Research Grants
‘Emerging Leader Award’ aims to attract new scientific talent to address challenges of Lyme disease
Portola Valley, California, December 5, 2017—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced a call for applications for three Bay Area Lyme Foundation ‘Emerging Leader Award’ grants, one for $250,000 and the other two for $100,000. These awards will be given to promising scientists who embody the future of leadership in Lyme disease research in the US. The award recipients will be researchers in academia or the private sector who have demonstrated professional and scientific leadership in the biomedical sciences and who can offer scientific rationale for a research project that can advance diagnostics or treatments for Lyme disease.
by Daniel Lynch, Founder & President, Medical Bill Gurus
This week, we have a guest post from Daniel Lynch. Daniel Lynch is the founder of Medical Bill Gurus, a patient and physician advocacy company that specializes in navigating the complex issues associated with healthcare and medical bills. His mission, he explains is to “utilize our wealth of information to ‘pay it forward’ to those who need assistance! … Although most claims for Lyme disease are typically at cash-only medical providers and not covered by insurance companies, we at Medical Bill Gurus have put together a process of breaking down bills, and identifying components of treatment that are covered by PPO insurance plans.”
Here he shares his perspective and some tips. Bay Area Lyme Foundation has no connection with Medical Bill Gurus and this post is not an endorsement of their services. At Bay Area Lyme, we are committed to supporting the community by ensuring access to information and resources to help them deal with Lyme disease.
Lyme disease, particularly with chronic or late-stage symptoms, can be a horribly frustrating and debilitating illness. Symptoms can persist despite complicated treatment regimens; therapies that seem successful at first may become less effective over time; and medications that work for some appear to have no effect for others. Add to that the high cost of treatment, the complicating challenges of co-infections, and insufficient insurance coverage for both traditional and alternative treatment, and it quickly becomes apparent why clinical studies offer potential for patients who are still suffering.
For many patients, the promise of participating in a clinical trial is not just the hope for new discoveries but a more immediate opportunity to access treatment options they may not otherwise be able to secure or afford. But is clinical research the “holy grail” for these patients who are seeking another option? What are the pros and cons of clinical research? What do you need to know?
On Wednesday, March 8, Dr. Sunjya Schweig and his wife, Lia Gaertner, together gave a deeply affecting and informative presentation sharing their personal and professional experiences with Lyme disease. The talk was part of the ongoing Distinguished Speaker Series. What follows is a synopsis of some of the highlights.
Lia Gaertner, a member of the Bay Area Lyme Foundation Science Committee, and Dr. Schweig, who is on the foundation’s Advisory Board, bring a wealth of professional expertise and knowledge to the table. But their story starts on a personal note, for it was just one month after Dr. Schweig started working in private practice that Lia — after 10 years of battling serious illness, unexplained symptoms, and debilitating physical and mental challenges — was finally diagnosed with Lyme disease. Together, the couple took what they describe wryly as a “rapid descent together down a rabbit hole” – a deep dive into Lyme, trying to learn as much as possible for their survival.
“Collaboration is the key to solving the myriad of challenges of Lyme disease, and we were excited to have the participation of so many researchers new to Lyme research,” said Wendy Adams, Science Committee, Bay Area Lyme Foundation. “It has been exciting to see such a wide range of expertise and enthusiasm come together to focus on solutions for this serious disease.”
California Strains of Lyme Bacteria May Survive Antibiotic Treatment, According to New Study
This new study funded by Bay Area Lyme Foundation identifies 20 FDA-approved compounds that are more effective in inhibiting persistent Lyme bacteria than standard treatment
Silicon Valley, CA, April 6, 2016—A laboratory study published today, funded by the Bay Area Lyme Foundation, is the first study to demonstrate that strains of Lyme bacteria present in California ticks are able to form persister bacteria, which do not respond well to treatment.The study is also the first to identify FDA-approved therapies that may be more effective in inhibiting these specific strains of persister bacteria in the lab than doxycycline, the most commonly prescribed treatment for Lyme disease. The study was conducted by Stanford School of Medicine researchers and published in the Open Access publication Drug Design, Development and Therapy. View full study here:http://www.dovepress.com/articles.php?article_id=26319
Theresa Wiles is a PSYCH-K® facilitator in Northern California. Her work involves helping patients to leverage their subconscious beliefs for positive outcomes. “Changing our thought patterns changes our ‘Field’ and we begin to create the reality we envision for ourselves. We start to act more intuitively, we experience more serendipity in our lives. The Universe and our subconscious mind starts assisting us in creating the life we envision for ourselves.”
Here, in this guest post, she shares a perspective about how these techniques might assist in the healing of long-term Lyme disease.
Biofilms that form in the human body are up to ten thousand times more resistant to antibiotics than free-floating bacteria, making them very difficult to treat medically. These biofilms are responsible for the extreme persistence of many difficult to treat illnesses like Legionnaire’s disease, Staphylococcus aureus (“Staph”), and infectious bronchitis, that can trouble patients with frustrating symptoms for years.
Some years ago researchers showed that biofilms might also be helping the Lyme-causing bacteria evade treatment.(1) These findings have excited Lyme researchers who have since been exploring various treatment strategies designed to target the entire bacterial colony. If successful, these treatments might bring long-needed relief to patients with late-stage or persistent Lyme disease where antibiotics have previously failed.
At Bay Area Lyme Foundation, we are also inspired by these discoveries and hopeful about the treatment options they may bring. Recently we invited Daina Zeng, a Senior Scientist at Agile Sciences, to talk about the work her team is doing adapting Agile’s proprietary non-toxic organic compounds to disperse these bacterial colonies (technology they have leveraged for medical, agricultural, and industrial uses). Her post follows.
(Note: Bay Area Lyme Foundation is a research and informational organization, not a medical entity. The Foundation does not advocate or endorse any particular treatment or clinical approach but is devoted to the sharing of information and the facilitation of new research in hopes that better diagnostics tools and therapies can be discovered. Please consult your physician or clinician for more information about specific or individual treatments.)
“In 2013, Woods Hole Oceanographic Institute discovered that the Lyme-causing Borreliaburgdorferi organism is manganese-dependent, because it substitutes manganese where almost all other organisms use iron for survival. By using manganese, the Borrelia is assisted in evading the immune system, which typically responds to foreign pathogens by starving them of iron. Further, manganese is important for the human body (helping to monitor blood sugar levels, supporting production of collagen for tissue repair, and even helping the central nervous system to function properly) and there is no easy way to shut down the manganese supply to these organisms.